Morgan Stanley assumed coverage of Abivax (ABVX) with an Equal Weight rating and $12 price target The Phase 2 results for obefazimod, Abivax’s miR-124 upregulator, point to its potential as a safe, oral option for ulcerative colitis patients, the analyst tells investors in a research note. However, the firm believes the upcoming Phase 3 induction readout in Q3 “will be key in defining next steps for the company.” The Equal Weight rating assumes the shares could remain range-bound until investors are presented with this data cut, contends Morgan Stanley.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Buy Rating for Abivax SA Driven by Promising Obefazimod Data and Market Potential
- Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025
- Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment
- Abivax management to meet with Piper Sandler
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue